IDEXX Announces Planned CEO Succession; Michael Erickson to Succeed Jay Mazelsky

summarizeSummary

IDEXX Laboratories announced a planned CEO succession, promoting internal executive Michael Erickson to President and CEO, while current CEO Jay Mazelsky transitions to Executive Chair for an orderly handover.

check_boxKey Events

• CEO Transition Announced

  Jonathan (Jay) Mazelsky will step down as President and CEO, effective May 12, 2026, and transition to Executive Chair of the Board until his retirement in May 2027.

• New CEO Appointed

  Michael (Mike) Erickson, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will become President and CEO and join the Board on May 12, 2026.

• New CEO Compensation Details

  Dr. Erickson's compensation will include an annual base salary of $1,000,000, a target annual bonus of 120% of base salary, and a 2026 long-term incentive equity award with a target value of at least $7.8 million.

• Outgoing CEO Compensation as Executive Chair

  Mr. Mazelsky will receive an annual base salary of $1,150,000 as Executive Chair and a 2026 equity grant with a target value of at least $8.275 million.

auto_awesomeAnalysis

IDEXX Laboratories announced a planned and orderly CEO transition, with current President and CEO Jonathan (Jay) Mazelsky stepping down to become Executive Chair of the Board, effective May 12, 2026. Michael (Mike) Erickson, a long-time internal executive with nearly two decades of leadership experience at IDEXX, will assume the role of President and Chief Executive Officer and join the Board. This internal promotion and structured transition, with Mazelsky remaining as Executive Chair until his retirement in May 2027, signals continuity and stability in leadership. The new CEO's compensation package includes a $1 million base salary and a target annual bonus of 120% of base salary, along with a significant equity award, reflecting standard executive compensation for a company of this scale.